SCHEMBL5161934

SCHEMBL5161934

O=C(O)C1CC(O)c2ccc(F)cc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 1/20 0.40
CHRNB4 P30926 1/20 0.40
CHRNA3 P32297 1/20 0.40
CHRNA4 P43681 1/20 0.40
HSD11B1 P28845 1/20 0.38
KDM1A O60341 2/20 0.37
KDM1B Q8NB78 1/20 0.37
PTGDR2 Q9Y5Y4 2/20 0.36
ALDH1A1 P00352 3/20 0.35
TSHR P16473 2/20 0.35
KEAP1 Q14145 1/20 0.34
TDP1 Q9NUW8 2/20 0.34
KDM4E B2RXH2 1/20 0.34
PDPK1 O15530 1/20 0.34
LMNA P02545 1/20 0.34
HPGD P15428 1/20 0.34
NFKB1 P19838 1/20 0.34
APEX1 P27695 1/20 0.34
CYP2C19 P33261 1/20 0.34
HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4961337 0.79 CHRNB2 (0.35) CHRNB2CHRNB4CHRNA3CHRNA4KDM1A
SCHEMBL7826273 0.75 MTNR1A (0.43) PTGDR2ALDH1A1TSHRKDM4E
SCHEMBL19926708 0.73 ACHE (0.39) PTGDR2ALDH1A1TSHRKEAP1TDP1
SCHEMBL9535853 0.71 AKR1B1 (0.46) TDP1
SCHEMBL1340154 0.70 PIN1 (0.50) ALDH1A1TSHRLMNAHTT
SCHEMBL1337775 0.70 PIN1 (0.50) ALDH1A1TSHRLMNAHTT
SCHEMBL2789968 0.70 PIN1 (0.50)
SCHEMBL29609152 0.70 PIN1 (0.50)
SCHEMBL1340548 0.70 PIN1 (0.50) ALDH1A1TSHRLMNAHTT
SCHEMBL5156270 0.69 MAOB (0.43) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050256164-A1 NK1 and NK3 antagonists PFIZER INC 2005-11-17 US claimed
EP-1748984-A1 PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS Pfizer Products Inc. (US) 2007-02-07 EP disclosed
WO-2005110987-A1 PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS PFIZER PRODUCTS INC. (US) 2005-11-24 WO disclosed
US-20050256164-A1 NK1 and NK3 antagonists PFIZER INC 2005-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256164-A1 NK1 and NK3 antagonists TAC3, TACR1, TACR2 CHRNB2 793/4885CHRNB4 531/4885CHRNA3 179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.